Health ❯ Healthcare ❯ Medical Research ❯ Clinical Trials

Cancer Treatment

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Early survival data remain immature, with results suggesting the noncovalent BTK inhibitor could influence frontline treatment choices.

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

OS Therapies Posts Significant 2-Year Survival Gain for OST-HER2 in Metastatic Osteosarcoma

Once-Monthly Subcutaneous Amivantamab Plus Lazertinib Shows High Response in Untreated EGFR‑Mutated NSCLC

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Pivekimab Sunirine Shows 85% Response Rate in BPDCN Trial

Avelumab and Cetuximab Combo Quadruples Progression-Free Survival in Advanced cSCC